Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
470-09-142 ISMRM Abstract

Quantitative MRI detects antiretroviral drug-induced maturation delays in cerebral organoids

Primary: Preclinical Animal & in vitro MR - Biomarkers
Secondary: Neuro - Infectious Disease
470-09-142 · MRI in Infectious Diseases · Tuesday, 12 May, 4:00 PM–4:55 PM · Traditional Posters | Exhibition Hall
Keywords: Cerebral organoids HIV exposure Apparent Diffusion Coefficient (ADC) Antiretroviral drugs Dolutegravir
Accepted
Manjeet Kumar1, Christine Adalikwu1, Jhyama Gurung1, Yutong Liu1,2, Aditya N Bade 1, Balasrinivasa R Sajja2
1Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, United States of America
2Department of Radiology, University of Nebraska Medical Center, Omaha, United States of America
Presenting Author: Aditya N Bade

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Hill A, Clayden P, Thorne C, Christie R, Zash R. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. J Virus Erad. 2018 Apr 1;4(2):66-71. doi: 10.1016/S2055-6640(20)30247-8. PMID: 29682297; PMCID: PMC5892677. [doi] [pmid]
2. Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24. PMID: 30037297; PMCID: PMC6550482. [doi] [pmid]
3. Schnoll JG, Temsamrit B, Zhang D, Song H, Ming GL, Christian KM. Evaluating Neurodevelopmental Consequences of Perinatal Exposure to Antiretroviral Drugs: Current Challenges and New Approaches. J Neuroimmune Pharmacol. 2021 Mar;16(1):113-129. doi: 10.1007/s11481-019-09880-z. Epub 2019 Sep 11. PMID: 31512167; PMCID: PMC7064402. [doi] [pmid]
4. Bade AN, McMillan JM, Liu Y, Edagwa BJ, Gendelman HE. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. Mol Neurobiol. 2021 Nov;58(11):5703-5721. doi: 10.1007/s12035-021-02508-5. Epub 2021 Aug 14. PMID: 34390469; PMCID: PMC8599359. [doi] [pmid]
5. Foster EG, Sillman B, Liu Y, Summerlin M, Kumar V, Sajja BR, Cassidy AR, Edagwa B, Gendelman HE, Bade AN. Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model. Front Pharmacol. 2023 Dec 12;14:1294579. doi: 10.3389/fphar.2023.1294579. PMID: 38149054; PMCID: PMC10750158. [doi] [pmid]
6. Kobal L, Surlan Popovic K, Avsenik J, Vipotnik Vesnaver T. ADC values as a biomarker of fetal brain maturation. Radiol Oncol. 2023 Jun 21;57(2):178-183. doi: 10.2478/raon-2023-0022. PMID: 37341193; PMCID: PMC10286892. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/470-09-142